Paradigm Biocapital Advisors LP Cogent Biosciences, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 10,352,449 shares of COGT stock, worth $120 Million. This represents 3.47% of its overall portfolio holdings.
Number of Shares
10,352,449
Previous 8,963,655
15.49%
Holding current value
$120 Million
Previous $53.7 Million
38.44%
% of portfolio
3.47%
Previous 2.75%
Shares
6 transactions
Others Institutions Holding COGT
# of Institutions
203Shares Held
117MCall Options Held
2.84MPut Options Held
828K-
Kynam Capital Management, LP Princeton, NJ8.49MShares$98.1 Million7.28% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$84.2 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$80.4 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$75.3 Million0.0% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$71.9 Million13.7% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $760M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...